Abatacept and Ptcy Based Gvhd Prophylaxis with CNI/Sirolimus for Haploidentical HCT: Donor KLRC2 Genotype Impacts Outcome
In: Blood, Jg. 142 (2023-11-02), Heft 1, Number 1 Supplement 1, S. 4928-4928
serialPeriodical
Zugriff:
Background:Abatacept (Abata, CTLA4Ig), an inhibitor of a key T cell costimulation pathway has recently been approved for GVHD prophylaxis following unrelated donor HCT in combination with CNI/MTX. In 2015, we had developed a novel protocol combining Abata and PTCy for HCT from haploidentical family donors (HFD). We analysed the impact of donor immunogenetics and immune reconstitution on the long-term outcome of 182 patients receiving HFD-HCT on this protocol.
| Titel: |
Abatacept and Ptcy Based Gvhd Prophylaxis with CNI/Sirolimus for Haploidentical HCT: Donor KLRC2 Genotype Impacts Outcome
|
|---|---|
| Autor/in / Beteiligte Person: | Jaiswal, Sarita Rani ; Agarwal, Mahak ; Baligar, Prakash ; Biswas, Subhrajit ; Das, Bhudev C ; Bacigalupo, Andrea ; Chakrabarti, Suparno |
| Zeitschrift: | Blood, Jg. 142 (2023-11-02), Heft 1, Number 1 Supplement 1, S. 4928-4928 |
| Veröffentlichung: | 2023 |
| Medientyp: | serialPeriodical |
| ISSN: | 0006-4971 (print) ; 1528-0020 (print) |
| DOI: | 10.1182/blood-2023-188981 |
| Sonstiges: |
|